About
Fenel M. Eloi has served on the 908 Devices board since February 2021. He was most recently CFO and then COO of Cell Signaling Technology and previously COO and CFO of Interleukin Genetics and CFO of LifeCell Corp and Genome Therapeutics. He serves on the boards of Standard BioTools and several private life-science companies and is a Managing Partner at P&M Capital Partners. He holds an MBA from Anna Maria College and a B.A. in Business and Finance from Lee University.
Roles
908 Devices Inc.
Director · Current role
February 2021–present
Cell Signaling Technology, Inc.
Chief Financial Officer and then Chief Operating Officer
September 2005 - March 2018
Interleukin Genetics, Inc.
Chief Operating Officer and Chief Financial Officer
—
External Roles
Standard BioTools Inc.
Director and Audit Committee member
—
P&M Capital Partners
Managing Partner
—
Director Compensation
FY 2025Fees earned or paid in cash
$65,417
ComponentBoard and committee cash retainers earned in FY2025
Stock awards
$101,257
ComponentAnnual RSU grant, ASC 718 grant-date fair value
Option awards
$33,753
ComponentAnnual NQSO grant, ASC 718 grant-date fair value
Total
$200,427
Also at 908 Devices Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.